linjc16/ctgov huggingface dataset:
Pulmonary Surfactant(PS) Therapy at High Altitude Area

Study Overview
=================
Brief Summary
-----------------
The traditional concept believes that the etiology of neonatal respiratory distress syndrome (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is still one of the major causes of mortality and morbidity in newborns, especially premature infants[1].In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal medicine [2].Combined with clinical practice and experience,and through Meta analysis of related randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For RDS in preterm infants whose gestation is <35 weeks ,surfactant replacement therapy is also more effective than in nearly term and full term infants.Therefore, in the analysis of cases of different gestational age groups,the investigators should focus on the study of premature infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in high altitude area,this retrospective study conducts statistics and analysis of recently three-year cases in some hospital of high altitude area,to explore the treatment effect of the high altitude region and the impact of altitude on the treatment.

Detailed Description
-----------------
in order to explore feasibility and efficacy for PS treatment of newborn RDS in high-altitude area ,and its efficacy at different altitudes, the investigators conduct a multi-center retrospective study of RDS cases in Qinghai and Tibet these two high-altitude area,and use RDS cases under the unique conditions to do statistics and analysis.

Official Title
-----------------
A Multicenter Study of Pulmonary Surfactant(PS) Therapy in the Treatment of Neonatal Acute Respiratory Distress Syndrome(RDS) at High Altitude Area

Conditions
-----------------
NRDS, Surfactant

Intervention / Treatment
-----------------
* Drug: surfactant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with respiratory distress syndrome(RDS) Exclusion Criteria: major congenital abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 12 Hours

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the intubation rate | the effect of PS treatment for NRDS | one week | 
| the incidence of NRDS in different altitudes | different altitudes may result in different rate of NRDS | one week |
Unicompartmental Knee Arthroplasty vs. High Tibial Osteotomy for Medial Knee Osteoarthritis (UNIKORN): a Study Protocol of a Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Unicompartmental knee arthroplasty (UKA) and High Tibial Osteotomy are both valid treatment options for isolated medial knee osteoarthritis. Literature to date is lacking high grade evidence of the outcomes between these procedures. This is a study protocol for randomized controlled trial comparing UKA vs HTO in late stage medial knee osteoarthritis.

Official Title
-----------------
Unicompartmental Knee Arthroplasty vs. High Tibial Osteotomy for Medial Knee Osteoarthritis (UNIKORN): a Study Protocol of a Randomized Controlled Trial

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Procedure: Unicompartmental knee arthroplasty
* Procedure: High tibial osteotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Isolated KL 3-4 medial knee arthrosis Varus > 3 degrees Age 45-65 years Exclusion Criteria: Post-traumatic arthrosis Arthrosis in the lateral compartment more than KL grade I in MRI Post- traumatic arthrosis Instability Malignancy Obesity

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Unicompartmental knee osteoarthritis<br> | Procedure: Unicompartmental knee arthroplasty<br>* Medial Unicompartmental knee arthroplasty<br>|
| Active Comparator: High tibial osteotomy<br> | Procedure: High tibial osteotomy<br>* Medial open wedge high tibial osteotomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KOOS |  | 1- year |
A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households

Study Overview
=================
Brief Summary
-----------------
This study will test the effectiveness of face masks and hand cleaning in preventing the spread of influenza within households

Detailed Description
-----------------
Randomised controlled trial of surgical masks and alcohol hand wash among approximately 6069 Hong Kong residents who have a household member diagnosed with influenza. Influenza in index member and secondary infection will be documented with rapid influenza tests and PCR. Minimal risk to participants.

Official Title
-----------------
A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Behavioral: hand hygiene
* Other: health education
* Device: face masks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Member of family with influenza infected member Exclusion Criteria: Age less than 2 yr
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>health education | Other: health education<br>* Proper nutrition, etc.<br>|
| Experimental: 2<br>hand hygiene | Behavioral: hand hygiene<br>* alcohol-based hand wash<br>|
| Experimental: 3<br>masks and hand hygiene | Behavioral: hand hygiene<br>* alcohol-based hand wash<br>Device: face masks<br>* face masks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| secondary influenza infection |  | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
influenza, masks, transmission, hand hygiene, non-pharmacologic interventions
Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye

Study Overview
=================
Brief Summary
-----------------
The purpose of this retrospective study is to assess corneal changes (keratometry, pachymetry) and change in visual acuity (VA) in keratoconus patients after unilateral crosslinking treatment compared to the untreated fellow eye. The corneal measurements obtained preoperatively and 2 to 14 months postoperatively using a Pentacam rotating scheimpflug camera are analyzed. Furthermore, pre-existing or actual ocular pathology or/and ocular surgeries as potential factors involved in treatment outcome are also evaluated.

Official Title
-----------------
Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye

Conditions
-----------------
Keratoconus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Keratoconus patients after unilateral crosslinking treatment Exclusion Criteria: Morphological changes of the cornea caused be ocular infection or trauma (e.g. corneal scarring) Other pre-existing corneal surgery (e.g. corneal transplantation, implantation of intrastromal corneal ring segments)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in maximum keratometry (Kmax) as measured by the Pentacam HR |  | after completion of data collection based on the measurements preoperatively and 2-14 months postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in corneal thickness as measured by the Pentacam HR |  | retrospective analysis from preoperatively to 2-14 months postoperatively | 
| Change in visual acuity (VA) |  | retrospective analysis from preoperatively to 2-14 months postoperatively | 
| Evaluation of pre-existing ocular pathology or/and ocular surgery as potential factors involved in treatment outcome |  | retrospective analysis from preoperatively to 2-14 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
crosslinking, keratoconus, keratometry, pachymetry, pentacam
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

Official Title
-----------------
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

Conditions
-----------------
Perception of Physicians & Patients of AMD

Intervention / Treatment
-----------------
* Drug: Symbicort


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone). Exclusion Criteria: Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1 Upper Respiratory Tract Infection in the previous four weeks Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study. Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate. Previous enrollment in a clinical study Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Symbicort|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction with the adjustable maintenance dosing schedule |  | Throughout the study | 
| Physicians' satisfaction with the adjustable maintenance dosing schedule |  | Throughout the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SYMBICORT AMD
Gender and Proper Size of Oropharyngeal Airway: Pilot Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the adequacy of mask ventilation with the different sized-oropharyngeal airway.

Conditions
-----------------
Adult Patients Undergoing Surgery That Requires General Anesthesia

Intervention / Treatment
-----------------
* Device: No. 7 oral airway
* Device: No. 8 oral airway
* Device: No. 9 oral airway


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients undergoing surgery that requires general anesthesia Exclusion Criteria: anticipated difficult intubation patients without teeth or with loose teeth cervical spine disease body mass index over 35 kg/m2 pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: No. 7 oral airway<br> | Device: No. 7 oral airway<br>* the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)<br>|
| Experimental: No. 8 oral airway<br> | Device: No. 8 oral airway<br>* the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)<br>|
| Active Comparator: No. 9 oral airway<br> | Device: No. 9 oral airway<br>* the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the proportion of patients whose oropharyngeal airway is proper | The oropharyngeal airway will be inserted into the patient's mouth. Investigators will check the laryngeal view using fiberoptic bronchoscope and the adequacy of ventilation after the investigator ventilates the patient using the face mask. If both the laryngeal view and ventilation are appropriate, the size of oropharyngeal airway will be considered as the proper size for the patient. | up to 10 minutes after the start of anesthetic induction |
Tolerance of Healthy, Term Infants to Infant Formulas

Study Overview
=================
Brief Summary
-----------------
To assess the gastrointestinal tolerance of healthy full-term infants fed either experimental formula or a control formula

Official Title
-----------------
Tolerance of Healthy, Term Infants to Infant Formulas

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Milk based formula A
* Other: #2 Standard formula
* Other: #3 Human Milk
* Other: Milk based formula C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: judged to be in good health. singleton from a full term birth with a gestational age of 37-42 weeks birth weight was > 2490 g ( 5 lbs 8 oz) between 0 and 8 days of age at enrollment. Infant's parent(s) or a LAR has voluntarily signed and dated an ICF, approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study. Exclusion Criteria: An adverse maternal, fetal or infant medical history thought by the investigator to have potential for effects on tolerance, growth, and/or development, including, but not limited to suspected maternal substance abuse. Infant has been treated with antibiotics.

Ages Eligible for Study
-----------------
Maximum Age: 8 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Milk based formula A<br>Experimental milk based infant formula | Other: Milk based formula A<br>* feed as per HCP directions<br>* Other names: AN0710A;|
| Active Comparator: Standard formula<br>standard milk based infant formula | Other: #2 Standard formula<br>* Feed as per HCP directions<br>* Other names: AN0710B;|
| Other: Reference<br>Human milk | Other: #3 Human Milk<br>* Feed as per HCP directions<br>* Other names: Human Milk;|
| Experimental: Milk based formula C<br>Experimental milk based infant formula | Other: Milk based formula C<br>* Feed as per HCP direction<br>* Other names: AN0710C;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean rank stool consistency (MRSC) |  | Study Day 1 to Visit 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRSC, percent watery stools, average number of stools per day, percent of feedings with spit-up and/or vomiting |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy term infants
Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The overarching goal of this prospective cohort study is to test the hypotheses that greater severity of hyposmia is associated with increased risk of cognitive decline in PD and that worsening hyposmia parallels progressive cholinergic limbic denervation. To achieve the goals of this project, patients with PD without dementia or at-risk of dementia or with dementia will undergo longitudinal olfactory, cognitive and clinical testing for 2-4 years. AChE [11C]PMP or VAchT (vesicular acetylcholine transporter) [F18]-FEOBV PET will be performed both at study entry and at 2-years (± 6 months) follow-up. Brain MRI scans will also be performed at study entry and at 2-years (± 6 months) follow-up. Brain Beta-amyloid PET will be performed at study entry or at 2 years (± 6 months). Annual olfactory testing will be performed to better understand dynamic changes underlying the clinical and PET outcome measures.

Detailed Description
-----------------
Smell functions will be assessed using a test battery of odor identification, odor memory, and odor discrimination tests.

Official Title
-----------------
Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Parkinson disease Hoehn & Yahr stage 2 and higher, and/or duration of motor disease 5 years or longer 50 and older Exclusion Criteria: other disorders which may resemble PD subjects with definite dementia subjects with unstable or severe medical disorders subjects receiving neuroleptic, anticholinergic, or cholinesterase inhibitor drugs subjects in whom MRI imaging is contraindicated subjects who have received ionizing radiation that would, together with the current project exposures, exceed exposure limits permissible to research volunteers pregnant

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson disease group<br>Subjects with Parkinson disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Olfactory testing |  | Yearly follow up visits | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson disease, smell, cognitive
Comparing of Long Bout and Short Bouts of Similar Volume of Walking in Obese on Weight Loss During a Weight Loss Program

Study Overview
=================
Brief Summary
-----------------
The purpose of this present study is to determine if a daily walking program of 50 continuous minutes (long bout) or two 25-minute bouts (short bouts) in similar volume on body weight, abdominal fat mass deposition and cardiometabolic measures in overweight and obese women receiving a low calorie diet for 24 weeks.

Conditions
-----------------
Obesity, Overweight

Intervention / Treatment
-----------------
* Behavioral: Diet+ short term versus long -term physical activity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have Body mass index (BMI) between 27-35 kg/ m². were sedentary (reported exercising <20 min/d for the previous 6 month) and healthy Must be able to have moderate exercise. Must be interested to have weight loss. Exclusion Criteria: Participating in a research project involving weight loss or physical activity in the previous six months. Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. Taking medication that could affect metabolism or change body weight. Report heart problems, chest pain, and cancer within the last five years. Smoking Menopause Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diet+ short -term physical activity (DST)<br> | Behavioral: Diet+ short term versus long -term physical activity<br> <br> |
| Experimental: Diet+ long -term physical activity (DLT)<br> | Behavioral: Diet+ short term versus long -term physical activity<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss |  | 24 weeks | 
| Body mass index reduction |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| waist circumference |  | 24 weeks | 
| Fasting plasma glucose level |  | 24 weeks | 
| lipid profiles |  | 24 weeks | 
| Insulin resistance (HOMA) |  | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
long bout physical activity, short bout physical activity, Caloric Restriction